For the quarter ended March 2025, Cardinal Health (CAH) reported revenue of $54.88 billion, down 0.1% over the same period last year. EPS came in at $2.35, compared to $2.08 in the year-ago quarter.The reported revenue represents a surprise of -0.27% over the Zacks Consensus Estimate of $55.03 billion. With the consensus EPS estimate being $2.15, the EPS surprise was +9.30%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine ...

Cardinal Health (CAH) came out with quarterly earnings of $2.35 per share, beating the Zacks Consensus Estimate of $2.15 per share. This compares to earnings of $2.08 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 9.30%. A quarter ago, it was expected that this prescription drug distributor would post earnings of $1.75 per share when it actually produced earnings of $1.93, delivering a surprise of 10.29%.Over the last four qu ...

Revenue and Earnings - Revenue for Q3 Fiscal 2025 was flat at $54.9 billion and decreased 3% to $162.4 billion for the nine months, primarily due to the expiration of OptumRx contracts[14]. - GAAP operating earnings increased to $730 million for Q3 and $1.8 billion for the nine months, while non-GAAP operating earnings rose 21% to $807 million and 14% to $2.1 billion, driven by branded pharmaceutical sales growth[16]. - GAAP diluted EPS for Q3 increased 96% to $2.10 and 118% to $5.44 for the nine months, primarily due to improved operating earnings and absence of prior goodwill impairment charges[20]. - Non-GAAP operating earnings for Q3 Fiscal 2025 were $807 million, representing a 21% growth rate compared to the prior year[119]. - Net earnings for the nine months ended March 31, 2025, were $1,326 million, compared to $620 million for the same period in 2024, representing a 113% increase[145]. Cash Flow and Liquidity - Cash and equivalents decreased to $3.3 billion at March 31, 2025, from $5.1 billion at June 30, 2024, with net cash provided by operating activities at $870 million[22]. - Cash flows from operating activities for the nine months ended March 31, 2025, were $870 million, down from $1,680 million in 2024, indicating a decrease of 48%[145]. - Total cash and equivalents at the end of the period was $3,326 million, down from $3,746 million at the end of the same period in 2024, marking a decrease of 11%[145]. - The company had $4.9 billion accrued related to opioid litigation settlements as of March 31, 2025, with payments totaling $797 million made during the nine months ended March 31, 2025[87]. Acquisitions and Investments - Cardinal Health deployed $1.1 billion for the Integrated Oncology Network acquisition and $2.8 billion for a 73% ownership interest in GI Alliance during the nine months ended March 31, 2025[23]. - The acquisition of GI Alliance is expected to positively impact segment revenue and profit while increasing amortization and acquisition-related costs[29]. - Cardinal Health completed the acquisition of Advanced Diabetes Supply Group for $1.1 billion, which will be reported in the at-Home Solutions segment[28]. - The acquisition of Integrated Oncology Network (ION) was completed for $1.1 billion in cash, supporting over 50 practice sites across 10 states[165]. - The acquisition of GI Alliance (GIA) was completed for approximately $2.8 billion in cash, with a 73% ownership interest[167]. Segment Performance - Pharma segment revenue for the three months ended March 31, 2025 was $50.4 billion, relatively flat compared to the prior year, while revenue for the nine months decreased 3% to $149.3 billion due to the expiration of OptumRx contracts[46]. - Global Medical Products and Distribution segment revenue increased 2% to $3.2 billion for the three months and $9.4 billion for the nine months ended March 31, 2025, primarily due to higher volumes from existing customers[47]. - Total segment profit for the three months ended March 31, 2025 increased 17% to $835 million, and for the nine months, it increased 13% to $2.1 billion, reflecting strong performance across segments[54]. Costs and Expenses - SG&A expenses for the three months ended March 31, 2025 increased 4% to $1.3 billion, and for the nine months, they increased 5% to $3.9 billion, primarily due to MSO platform acquisitions and higher costs to support sales growth[51]. - Interest expense for the three months ended March 31, 2025 increased to $74 million, and for the nine months, it increased to $141 million, primarily due to new debt financing[68]. - Restructuring and employee severance costs for Q3 Fiscal 2025 amounted to $28 million, while amortization and other acquisition-related costs were $152 million[119]. Tax and Goodwill - The effective tax rate for the three months ended March 31, 2025, was 23.6%, compared to 23.3% for the same period in 2024[69]. - During the nine months ended March 31, 2024, the company recognized pre-tax goodwill impairment charges of $675 million related to the GMPD segment, resulting in a net tax benefit of $56 million for fiscal 2024[70]. - Goodwill increased from $4.725 billion at June 30, 2024, to $8.906 billion at March 31, 2025, primarily due to the acquisitions of ION and GIA[187]. Shareholder Returns - The company approved a quarterly dividend of $0.5056 per share, amounting to an annualized rate of $2.02 per share, paid to shareholders on specified dates[89]. - The company has $2.7 billion authorized for share repurchases remaining under the program approved on June 7, 2023[135]. - The company’s share repurchase program activity resulted in a net cash outflow of $765 million for the nine months ended March 31, 2025, compared to $750 million in 2024, indicating ongoing commitment to returning capital to shareholders[145]. Risks and Uncertainties - Cardinal Health is facing potential additional costs and supply disruptions due to recent U.S. tariffs imposed on various countries[31]. - The company faces risks associated with entering new lines of business, including regulatory changes and competition from other healthcare organizations[128]. - The New York Opioid Stewardship Act created a $100 million annual assessment on manufacturers and distributors, with ongoing litigation regarding its constitutionality[204].

Cardinal Health (CAH) Q3 2025 Earnings Call May 01, 2025 08:30 AM ET Speaker0 Hello, and welcome to the Third Quarter Fiscal Year twenty twenty five Cardinal Health Incorporated Earnings Conference Call. My name is George, I'll be your coordinator for today's event. Please note this conference is being recorded. And for the duration of the call, your lines will be in listen only mode. However, you will have the opportunity to ask questions towards the end of the presentation. On your top of the keypad to as ...

Q3 FY25 Earnings Cardinal Health, Inc. May 1, 2025 © 2025 Cardinal Health. All Rights Reserved. 1 © 2025 Cardinal Health. All Rights Reserved. • Q3 FY25 Earnings Cautions Concerning Forward-Looking Statements Q3 Results © 2025 Cardinal Health. All Rights Reserved. 3 © 2025 Cardinal Health. All Rights Reserved. • Q3 FY25 Earnings This presentation contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. These st ...

Cardinal Health Reports Third Quarter Fiscal Year 2025 Results and Raises Fiscal Year 2025 Outlook Exhibit 99.1 FOR IMMEDIATE RELEASE DUBLIN, Ohio, May 1, 2025 – Cardinal Health (NYSE: CAH) today reported third quarter fiscal year 2025 revenues of $54.9 billion, flat to the third quarter of fiscal year 2024. Third quarter revenue increased 19% excluding the impact of the previously communicated customer contract expiration. Third quarter GAAP operating earnings increased to $730 million and GAAP diluted ear ...

Cardinal Health, Inc. (CAH) is scheduled to report third-quarter fiscal 2025 results on May 1, before market open.In the last reported quarter, the company’s adjusted earnings per share (EPS) of $1.93 surpassed the Zacks Consensus Estimate by 10.3%. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on all occasions, delivering an earnings surprise of 9.6%, on average. (See the Zacks Earnings Calendar to stay ahead of market-making news.)Let’s check out the factors that ...

The Zacks Medical - Dental Supplies industry in the Medical sector has a robust demand for dental services, driven by patient preferences for timely and convenient care, as well as policy initiatives aimed at enhancing access to dental health services. Dental practices witnessed heightened patient engagement over the past six months. This growth is driven by increased demand for various dental services, including cosmetic and preventive care.The pricing environment looks promising on the back of continued r ...

MELBOURNE, Australia and INDIANAPOLIS, April 08, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, Telix, the Company) today announces that it has selected Cardinal Health, Inc. (NYSE:CAH, Cardinal Health)) as one of its commercial radiopharmaceutical distributors to supply finished unit doses of Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), Telix's next-generation PSMA-PET imaging1 agent for prostate cancer in the United States (U.S.). Following ...

Economic Context - President Trump announced a "national economic emergency" and introduced a baseline 10% tariff on all countries to address a $1.2 trillion trade deficit, effective April 5 [1][5] - The tariffs are expected to escalate tensions and potentially lead to a global trade war, impacting market stability [8] Market Reaction - Following the announcement, Dow futures dropped over 800 points (2%), while S&P 500 futures and Nasdaq 100 futures fell by 2.7% and 3.6% respectively, indicating market apprehension [2] - Prior to the announcement, stocks had rallied as investors were optimistic about the tariffs being manageable [7] Investment Recommendations - In light of the market turmoil, it is advisable to invest in defensive sectors such as utilities, consumer staples, and healthcare [3] - Recommended stocks include: - **Southwest Gas Holdings, Inc. (SWX)**: Expected earnings growth rate of 17.1%, Zacks Rank 2, beta of 0.50, dividend yield of 3.45% [10] - **CMS Energy Corporation (CMS)**: Expected earnings growth rate of 7.8%, Zacks Rank 2, beta of 0.34, dividend yield of 2.89% [12] - **Molson Coors Beverage Company (TAP)**: Expected earnings growth rate of 6.2%, Zacks Rank 2, beta of 0.69, dividend yield of 3.07% [14] - **Sony Group Corporation (SONY)**: Expected earnings growth rate of 11.9%, Zacks Rank 1, beta of 0.94, dividend yield of 1.84% [16] - **Cardinal Health, Inc. (CAH)**: Expected earnings growth rate of 5.4%, Zacks Rank 2, beta of 0.61, dividend yield of 1.47% [18] Stock Characteristics - The recommended stocks are characterized as low-beta (beta greater than 0 but less than 1), which typically indicates lower volatility compared to the market [4]